Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen versus letrozole and fatty liver in premenopausal breast cancer
IRCT20221126056616N1Phase 2Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tamoxifen and letrozole in breast cancer (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoints: Alanine transaminase, Aspartate transaminase and 1 more. Started Dec 2022; status: completed.
02
Drugs
tamoxifenletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20221126056616N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221126056616N1.